About

Alfred P. Fishman is a faculty member in the Department of Medicine at the Perelman School of Medicine at the University of Pennsylvania. His contact information includes an office located at 1320 Blockley, Philadelphia, PA 19104, with a phone number of 215-662-3194 and an email address at fishmana@mail.med.upenn.edu. The page indicates his association with the university's medical faculty, but does not provide specific details about his research focus, background, or key contributions.

Research topics

• Family medicine
• Cardiology
• Intensive care medicine
• Medicine
• Internal medicine

Selected publications

• Survival in Patients with Primary Pulmonary Hypertension

  Annals of Internal Medicine · 2020 · 6 citations

  • Medicine
  • Internal medicine
  • Cardiology

  ▪ Objective: To characterize mortality in persons diagnosed with primary pulmonary hypertension and to investigate factors associated with survival. ▪ Design: Registry with prospective follow-up. ▪...

  Publisher

• Pulmonary Vascular and Circulatory Responses to Acute Hypoxia

  Progress in respiratory research/Progress in research in emphysema and chronic bronchitis/Progress in respiration research · 2015-04-15

  book-chapter1st authorCorresponding
  PublisherDOI

• Fishman's pulmonary diseases and disorders 2008

  2015-07-13

  article1st authorCorresponding

  Fishman's pulmonary diseases and disorders 2008 , Fishman's pulmonary diseases and disorders 2008 , کتابخانه مرکزی دانشگاه علوم پزشکی تهران

  Publisher

• Report of Committee on Definition of Emphysema

  American Review of Respiratory Disease · 2015-05-14

  article
  Publisher

• Comparative Biology of the Lung1

  American Review of Respiratory Disease · 2015-05-14

  article1st authorCorresponding
  Publisher

• Chronic Cor Pulmonale1, 2

  American Review of Respiratory Disease · 2015-05-14

  article1st authorCorresponding
  Publisher

• Foreword: The Natural History, Pathogenesis, Evaluation, and Treatment of Emphysema: Report of the National Emphysema Treatment Trial Research Group

  2012-12-20

  article1st authorCorresponding
  Publisher

• Anxiety is associated with diminished exercise performance and quality of life in severe emphysema: a cross-sectional study

  Respiratory Research · 2010-03-09 · 87 citations

  articleOpen access

  BACKGROUND: Anxiety in patients with chronic obstructive pulmonary disease (COPD) is associated with self-reported disability. The purpose of this study is to determine whether there is an association between anxiety and functional measures, quality of life and dyspnea. METHODS: Data from 1828 patients with moderate to severe emphysema enrolled in the National Emphysema Treatment Trial (NETT), collected prior to rehabilitation and randomization, were used in linear regression models to test the association between anxiety symptoms, measured by the Spielberger State Trait Anxiety Inventory (STAI) and: (a) six-minute walk distance test (6 MWD), (b) cycle ergometry peak workload, (c) St. Georges Respiratory Questionnaire (SRGQ), and (d) UCSD Shortness of Breath Questionnaire (SOBQ), after controlling for potential confounders including age, gender, FEV1 (% predicted), DLCO (% predicted), and the Beck Depression Inventory (BDI). RESULTS: Anxiety was significantly associated with worse functional capacity [6 MWD (B = -0.944, p < .001), ergometry peak workload (B = -.087, p = .04)], quality of life (B = .172, p < .001) and shortness of breath (B = .180, p < .001). Regression coefficients show that a 10 point increase in anxiety score is associated with a mean decrease in 6 MWD of 9 meters, a 1 Watt decrease in peak exercise workload, and an increase of almost 2 points on both the SGRQ and SOBQ. CONCLUSION: In clinically stable patients with moderate to severe emphysema, anxiety is associated with worse exercise performance, quality of life and shortness of breath, after accounting for the influence of demographic and physiologic factors known to affect these outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT00000606.

  PublisherOA PDFDOI

• Anxiety is associated with diminished exercise performance and quality of life in severe emphysema: a cross-sectional study

  Deep Blue (University of Michigan) · 2010-01-01

  articleOpen access

  Background: Anxiety in patients with chronic obstructive pulmonary disease (COPD) is associated with selfreported disability. The purpose of this study is to determine whether there is an association between anxiety and functional measures, quality of life and dyspnea. Methods: Data from 1828 patients with moderate to severe emphysema enrolled in the National Emphysema Treatment Trial (NETT), collected prior to rehabilitation and randomization, were used in linear regression models to test the association between anxiety symptoms, measured by the Spielberger State Trait Anxiety Inventory (STAI) and: (a) six-minute walk distance test (6 MWD), (b) cycle ergometry peak workload, (c) St. Georges Respiratory Questionnaire (SRGQ), and (d) UCSD Shortness of Breath Questionnaire (SOBQ), after controlling for potential confounders including age, gender, FEV1 (% predicted), DLCO (% predicted), and the Beck Depression Inventory (BDI). Results: Anxiety was significantly associated with worse functional capacity [6 MWD (B = -0.944, p < .001), ergometry peak workload (B = -.087, p = .04)], quality of life (B = .172, p < .001) and shortness of breath (B = .180, p < .001). Regression coefficients show that a 10 point increase in anxiety score is associated with a mean decrease in 6 MWD of 9 meters, a 1 Watt decrease in peak exercise workload, and an increase of almost 2 points on both the SGRQ and SOBQ. Conclusion: In clinically stable patients with moderate to severe emphysema, anxiety is associated with worse exercise performance, quality of life and shortness of breath, after accounting for the influence of demographic and physiologic factors known to affect these outcomes.

  PublisherOA PDF

• Prevalence and Clinical Correlates of Bronchoreversibility in Severe Emphysema

  Deep Blue (University of Michigan) · 2010-05-01

  article

  Chronic obstructive pulmonary disease (COPD) exhibits airflow obstruction that is not fully reversible. The importance of bronchoreversibility remains controversial. We hypothesised that an emphysematous phenotype of COPD would be associated with decreased bronchoreversibility. 544 patients randomised to the medical arm of the National Emphysema Treatment Trial formed the study group. Participants underwent multiple measurements of bronchoreversibility on a mean of four sessions over 1.91 yrs. They were also characterised by measures of symptoms, quality of life and quantitative measures of emphysema by computed tomography. Mean baseline forced expiratory volume in 1 s (FEV1) in this patient population is 24% predicted. 22.2% of patients demonstrated bronchoreversibility on one or more occasions using American Thoracic Society/European Respiratory Society criteria. Few patients (0.37%) had bronchoreversibility on all completed tests. Patients who demonstrated bronchoreversibility were more likely to be male, and have better lung function and less emphysema. 64% of patients demonstrated large (>=400 mL) changes in forced vital capacity (FVC). In a severe emphysema population, bronchoreversibility as defined by change in FEV1 is infrequent, varies over time, and is more common in males and those with less severe emphysema. Improvements in FVC, however, were demonstrated in the majority of patients.

  Publisher

Frequent coauthors

• Barry J. Make

  National Jewish Health

  42 shared

• Robert A. Wise

  Pulmonary and Critical Care Associates

  38 shared

• Fernando J. Martínez

  Cornell University

  38 shared

• J P Szidon

  Rush University Medical Center

  37 shared

• Frank C. Sciurba

  University of Pittsburgh

  35 shared

• Gerard J. Criner

  35 shared

• Jeffrey L. Curtis

  University of Michigan–Ann Arbor

  33 shared

• R. H. Ingram

  30 shared